The pharmaceutical industry relies heavily on a complex web of chemical synthesis, where specific intermediates play pivotal roles in bringing life-saving drugs to market. Among these essential compounds is 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline (CAS 183322-18-1), a key intermediate in the manufacturing process of Erlotinib. Understanding its significance is crucial for anyone involved in the procurement or synthesis of this important oncology therapeutic.

Erlotinib is a targeted therapy drug used to treat certain types of non-small cell lung cancer and pancreatic cancer. Its efficacy stems from its ability to inhibit the epidermal growth factor receptor (EGFR) tyrosine kinase. The synthesis of Erlotinib is a multi-step process, and 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline serves as a critical precursor, providing the core quinazoline structure that is subsequently functionalized to create the active pharmaceutical ingredient (API).

As an Erlotinib intermediate, the quality and purity of 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline are paramount. Impurities in this precursor can lead to unwanted by-products in the final API, potentially affecting its safety, efficacy, and regulatory approval. Therefore, sourcing this compound from a reputable pharmaceutical intermediate manufacturer with strict quality control measures is essential. Companies looking to buy 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline should prioritize suppliers who guarantee high purity, often exceeding 99.0%, and provide comprehensive analytical data.

For procurement professionals, identifying a reliable 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline supplier in China or other key manufacturing regions involves due diligence. Factors such as consistent batch-to-batch quality, competitive price for 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline, and robust supply chain management are critical. Engaging with a dedicated pharmaceutical intermediate supplier that understands the stringent requirements of the pharmaceutical sector ensures that your production timelines are met without compromising on quality.

The availability of this specific quinazoline derivative, often supplied as a white powder, facilitates its integration into standard chemical synthesis workflows. When planning to purchase CAS 183322-18-1, it is advisable to consult with potential suppliers about their production capacity and lead times, especially for larger commercial quantities.

In summary, 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline is more than just a chemical compound; it's a foundational element in the production of a vital cancer medication. By prioritizing quality and partnering with experienced manufacturers and suppliers, the pharmaceutical industry can ensure the consistent and safe production of Erlotinib, ultimately benefiting patients worldwide.